News

More Precision, More Effectiveness, More Safety – New Tools in the Fight Against Cancer

In September 2024, the NanoSanguis S.A. research team began work on the project Dextran Conjugates for Targeted Anticancer Therapy (2024/ABM/05/KPO/KP…

Series N Share Issue Nears Completion: All Share Subscription Agreements Signed, Raising PLN 24.5 Million in Total

NanoGroup S.A. is on track to successfully complete its Series N share issue. All share subscription agreements under the offering have been sign…

NanoGroup S.A. – Nominated for the Global Health Care Awards

NanoGroup S.A. has been nominated for the Global Health Care Awards in recognition of its development of NanOx technology – a comprehensive system des…

NanoGroup Initiates EU Certification of the NanOX Recovery Box

NanoGroup subsidiary NanoSanguis S.A. has entered into a cooperation agreement with notified body TÜV NORD Polska sp. z o.o. The agreement formally in…

Prestigious Recognition for Professor Tomasz Ciach – Among the Top 2% of Scientists Worldwide

We are proud to announce that Professor Tomasz Ciach, DSc, PhD, a Member of the Management Board of NanoGroup S.A. and Head of the Department of …

NanoGroup S.A. Summarises Its Key Achievements in 2025

NanoGroup S.A. looks back on its key achievements in 2025 – the best and most transformative year in the Company’s history. It was: a year o…

Media resources

Company logo

logotype.zip (1.27 MB)
Download
pp-thumbnail